Keyword: Acorda Therapeutics

Late last month, a court refused to block copies of Acorda’s Ampyra. So the New York drugmaker took matters into its own hands.

Biogen and UCB are already rumored to be eyeing an Acorda buyout. But one analyst thinks a host of other major players could join their ranks.

Earlier this month, reports said Acorda could be scouting buyers. And now, rumors are swirling as to who those potential bidders might be.

Approval of Acorda's candidate for an inhaled drug for Parkinson's disease is in jeopardy because of FDA questions about Acorda's manufacturing. 

After Acorda lost a key patent fight, putting its $493 million drug Ampyra in danger, a hedge fund is pushing the biotech to sell out.

Novartis loses Gilenya patent appeal, clearing way for early copies of the $3 billion multiple sclerosis med.

After two recent setbacks for his Coalition for Affordable Drugs, Kyle Bass may be ready to call it quits on his patent-challenge experiment.

Acorda Therapeutics plans to appeal a court’s recent decision to nix four of its five Ampyra patents. In the meantime, it’s preparing for the worst.

Acorda Therapeutics’ IP protection on Ampyra may have held up against an administrative patent challenge, but it didn't do the same in court.

Acorda Therapeutics can chalk up another win over patent challenger Kyle Bass and his Coalition for Affordable Drugs.